ReviewBiomedicines2026
S-Adenosylmethionine (SAM) and S-Adenosylhomocysteine (SAH) Monitoring Using Analytical Methods in Clinical Laboratory Practice: Where Are We?
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Metabolic Engineering of Pichia pastoris for S-Adenosylmethionine Overproduction via Transcriptomic-Guided Energy Reallocation.Biotechnology journal · 2026Article
- Epigenetic Modulation of Exercise Adaptation: The Role of Dietary Supplementation in Athletic Performance.Genes · 2026Review
- Synergistic Effects of Calcium Phosphate Biomaterials Combined with Honey on Osteochondral Regeneration: A Qualitative Study in an Animal Model.Bioengineering (Basel, Switzerland) · 2026Article
- Epitranscriptomics, immunometabolism, and NETosis: unlocking novel mechanisms of traditional Chinese medicine in COPD.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are essential intermediates in one-carbon metabolism and key regulators of cellular methylation capacity. Their concentrations and the SAM/SAH ratio are increasingly studied as biomarkers across metabolic, cardiovascular, neurological, and cancer-related diseases. This review outlines validated analytical methods for quantifying SAM and SAH, focusing primarily on liquid chromatography-tandem mass spectrometry (LC-MS/MS), which is considered the gold standard in both clinical and research settings. A comprehensive literature search identified studies on method development, validation, and clinical use of SAM and SAH measurements. Special attention is given to analytical challenges arising from their high polarity, structural similarity, endogenous presence, and limited stability. The review also discusses preanalytical variables, including biological matrix selection, sample handling, and storage conditions. LC-MS/MS methods are compared with alternative techniques, such as immunoassays, with respect to sensitivity, specificity, matrix effects, and clinical relevance. Additionally, the review summarizes the concentration ranges of SAM and SAH, and their ratio, in healthy and patient populations, noting current standardization limitations. Overall, the review highlights the importance of harmonized analytical protocols and matrix-specific validation to enable reliable clinical interpretation of SAM and SAH as methylation biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.